Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361493 | 0.93 | MAPT (0.70) | MAPTL3MBTL1TDP1ALDH1A1PKM | |
| SCHEMBL4542148 | 0.88 | LMNA (0.53) | MAPTL3MBTL1TDP1ALDH1A1RAB9A | |
| SCHEMBL16713330 | 0.88 | MAPT (0.56) | MAPTL3MBTL1TDP1ALDH1A1RAB9A | |
| SCHEMBL12004226 | 0.88 | MAPT (0.56) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL15687598 | 0.88 | POLB (0.61) | MAPTL3MBTL1ALDH1A1RAB9ANPC1 | |
| SCHEMBL8024498 | 0.87 | MAPT (0.53) | MAPTL3MBTL1TDP1ALDH1A1RAB9A | |
| SCHEMBL31072780 | 0.85 | KMT2A (0.50) | MAPTL3MBTL1TDP1ALDH1A1RAB9A | |
| SCHEMBL29343397 | 0.85 | KMT2A (0.50) | MAPTL3MBTL1TDP1ALDH1A1RAB9A | |
| SCHEMBL31237090 | 0.85 | MAPT (0.59) | MAPTL3MBTL1TDP1ALDH1A1PKM | |
| SCHEMBL2879386 | 0.84 | MAPT (0.60) | MAPTL3MBTL1TDP1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604260-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHIONOGI & CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2604260-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| WO-2009083526-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083526-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | MAPT 4730/4885L3MBTL1 4820/4885TDP1 4269/4885 |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | MAPT 4730/4885L3MBTL1 4820/4885TDP1 4269/4885 |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | PPARG, CDK5, CDK5R1 | MAPT 2787/4885L3MBTL1 3257/4885TDP1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.